Vir Biotechnology, Inc. (VIR) stock
Close on Nov 17, 2026Market cap $1.57BP/E –Yield –
Earnings
Vir Biotechnology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Vir Biotechnology's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 22, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | -$188.00K | -194.0% | -$0.57 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026after the close | $238.90M | +19808.3% | $0.47 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 6, 2026after the close | -$29.00K | -101.0% | -$0.85 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 23, 2026after the close | – | – | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025after the close | $200.00K | -91.7% | -$1.17 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025after the close | $1.20M | -61.3% | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025after the close | $3.00M | -94.7% | -$0.88 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 26, 2025after the close | $12.40M | -26.2% | -$0.76 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 31, 2024after the close | $2.40M | -7.7% | -$1.56 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 1, 2024after the close | $3.10M | -18.4% | -$1.02 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 2, 2024after the close | $56.40M | -10.5% | -$0.48 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 22, 2024after the close | $16.80M | -66.0% | -$0.86 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023after the close | $2.60M | -99.3% | -$1.22 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023after the close | $3.80M | – | -$1.45 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023after the close | $63.00M | -94.8% | -$1.06 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023after the close | $49.40M | -93.9% | -$0.76 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | $374.60M | +261.6% | $1.30 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 9, 2022after the close | -$40.60M | – | -$0.58 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $1.20B | – | $3.85 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 24, 2022after the close | $812.70M | – | $3.92 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021after the close | $103.60M | – | $0.82 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 25, 2021after the close | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 10, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
No open guidance: every period Vir Biotechnology guided for has been reported
Guidance history
Every forecast Vir Biotechnology put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Aug 1, 2024 | GAAP operating expense range | FY2024 | $580.00M – $610.00M | Lowered |
| May 2, 2024 | Stock-based compensation expense | FY2024 | $105.00M – $115.00M | New |
| May 2, 2024 | Restructuring charges | FY2024 | $25.00M – $35.00M | Lowered |
| May 2, 2024 | GAAP combined R&D and SG&A expense range | FY2024 | $650.00M – $680.00M | Raised |
| Feb 22, 2024 | GAAP combined R&D and SG&A expense range | FY2024 | $650.00M – $680.00M | New |
| Feb 22, 2024 | Stock-based compensation expense | FY2024 | $105.00M – $115.00M | Lowered |
| Feb 22, 2024 | Restructuring charges | FY2024 | $25.00M – $35.00M | Lowered |
| Feb 24, 2022 | sotrovimab collaboration revenues | FY2022 | $1.10B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Vir Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Results
- News
- News
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- News
- Results
See a number that looks wrong?